Effect of sacubitril/valsartan versus enalapril on glycaemic control in patients with heart failure and diabetes: a post-hoc analysis from the PARADIGM-HF trial

BACKGROUND: Diabetes is an independent risk factor for heart failure progression. Sacubitril/valsartan, a combination angiotensin receptor-neprilysin inhibitor, improves morbidity and mortality in patients with heart failure with reduced ejection fraction (HFrEF), compared with the angiotensin-conve...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Lancet Diabetes Endocrinol
Autors principals: Seferovic, Jelena P, Claggett, Brian, Seidelmann, Sara B, Seely, Ellen W, Packer, Milton, Zile, Michael R, Rouleau, Jean L, Swedberg, Karl, Lefkowitz, Martin, Shi, Victor C, Desai, Akshay S, McMurray, John J V, Solomon, Scott D
Format: Artigo
Idioma:Inglês
Publicat: 2017
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5534167/
https://ncbi.nlm.nih.gov/pubmed/28330649
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S2213-8587(17)30087-6
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars